Sluchay uspeshnoy terapii nilotinibom (Tasignoy) patsientki s Ph-pozitivnymkhronicheskim mieloleykozom v khronicheskoy faze s rezistentnost'yu k interferonui Gliveku
- Authors: Afanas'eva NA1, Gusarova GA2
-
Affiliations:
- Гематологический научный центр РАМН
- Гематологический научный центр РАМН,Москва
- Issue: Vol 10, No 3 (2008)
- Pages: 57-58
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26735
- ID: 26735
Cite item
Full Text
Abstract
Всвязи с выдающимися результатами, достигнутыми при применении ингибитора Bcr-Abl-тирозинкиназы иматиниба (Гливек®, Новартис Фарма), данный препарат стал стандартом терапии больных хроническим миелолейкозом (ХМЛ) на всех стадиях болезни. Применение Гливека в качестве препарата первой линии терапии в хронической фазе (ХФ) ХМЛ позволило достичь полного гематологического ответа (ПГО) у 97%, полного цитогенетического ответа (ПЦО) у 83% (данные 6 лет наблюдения). Прогрессия в фазу акселерации/бластного криза (ФА/БК) зафиксирована всего у 6% больных за весь период наблюдения, при этом не отмечено прогрессирования заболевания ни у одного пациента между 5 и 6 годом терапии.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
N A Afanas'eva
Гематологический научный центр РАМНотделение химиотерапии лейкозов и патологии эритрона
G A Gusarova
Гематологический научный центр РАМН,Москваотделение химиотерапии лейкозов и патологии эритрона
References
- Hochhaus A, Drucker B.J., Larson R.A. IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood. 2007; 110 (11): 25.
- Silver R.T., Talpaz M, Sawyers C.L. et al. Four Years of Follow - Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. Blood 2004; 104 (11): 23.
- O’Brien S.G., Gulihot F, Larson R.A et al. IRIS nvestigetors. Imatinib compared with interferon and low - dose cytarabine for newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994–1004.
- Kantarjian H, Sawyers C., Hochhaus A et al. International STI 571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645–52.
- Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leucemia. 2004; 18(8):1321–31.
- Kantarjian H.M., Larson R.A., Gulihot F et al. J. Declining rates of adverse events (AEs), rare occurrence of serios AEs (SAEs), and unexpected long - term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib in the internationalrandomised study of interferon vs STI571(IRIS). Poster, ASH 2006.
- Hochhaus A, Kreil S, Corbin A.S. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leucemia 2002; 16(11): 2190–6.
- Brandford S, Hughes T. Detection of Bcr-Abl mutations and resistance to imatinib mesylate. Methods Mol Med 2006; 125:93–106.
- Jiang X., Zhao Y, Smith C et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to Bcr-Abl targeted therapies. Leucemia 2007; 21:926–35.
- Soverini S, Martinell G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up - front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid leukemia. J Clin Oncol 2005; 23(18): 4100–9.
- Weisberg E, Manley P.W., Breitenstein W et al. Characterization of AMN 107, a selective inhibitors of wild - type and mutant Bcr-Abl. Cancer Cell 2005; 7:129–41.
- Nagar B, Bornman W.G., Pellicena P et al. Crystal structures of the kinase domain c-abl in complex with the small molecule ingibitors PD 173955 and imatinib (STI-571)Cancer Res 2002; 62(15): 4236–43.
- Kantarjian H.M., Hochhaus A, Cortes J et al. Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib- Resistance or Intolerance. Blood; 2007; 110 (11): 226a (abs. 735).
- Cortes J, Jabbour E, Hochhaus A et al. Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib - Intolerant Philadelphia- Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). Blood 2007; 110 (11): 315a (abstr. 1040).